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doned in the last decade. However a new generation of vaccines
wasborn,usingbiomolecular techniques. Called “chimerivax” tech-
nique, it uses the yellow fever (YF) 17D vaccine where the original
genes of proteins prM and E where replaced by genes coding the
proteins prM and E of each denguevirus, creating four YF virions
expressing DEN 1,2,3,4 antigens (in phase III clinical trials). Other
similar attempts have produced DEN/DEN chimeric virions, where
an attenuated serotype, is the frame of a 4-component dengue
vaccine (in phase I/II clinical trials). These vaccines show good per-
spectives of safety and immunogenicity against dengue disease.
Finally, at least two inactivated vaccines (prM and E proteins of
four serotypes) are being developed at phase I clinical trials. In
conclusion, several dengue vaccines are in the pipeline, with good
perspectives for dengue prevention.
http://dx.doi.org/10.1016/j.ijid.2014.03.474
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Mediators of vascular leak in dengue
G.N. Malavige
University of Sri Jayawardenapura, Nugegoda, Sri
Lanka
Increased vascular permeability leading to plasma leakage is
the hall mark of dengue haemorrhagic fever (DHF). The media-
tors that cause vascular leak in currently not know. As platelet
activating factor (PAF) and other lipid mediators such as sphin-
gosine 1 phosphate (S1P) are associated with increase in vascular
permeability in many disease conditions, we set out to investigate
the role of these mediators in acute dengue infection. Serum PAF,
PAF receptor, PAF-AH and SIP levels were done 45 patients with
conﬁrmed acute dengue infection and 12 healthy dengue seropos-
itive individuals. Serum PAF levels, IL-10, dengue NS1 antigen and
dengue IgG antibody levels were done in 15 patients in daily blood
samples collected throughout the course of their hospital stay. Dis-
ease severity was classiﬁed based on the WHO 2011 guidelines
for diagnosis and management of dengue infection. The effect of
PAF, PAF antagonists and serum of dengue serum on human umbil-
ical vein endothelial cell lines (HUVEC) were evaluated by confocal
microscopy. PAF levels were signiﬁcantly higher in patients with
acute dengue infection (p=0.001) when compared to healthy indi-
viduals. Although not signiﬁcant the PAF levels were higher in
those with DHF (mean 343.2, SD±437.7 ng/ml) when compared
to those with DF (mean204.7, SD±484.4 ng/ml). PAF-AH levels
were also signiﬁcantly higher in those with DHF. The PAF and IL-
10 levels were highest just before the onset of the critical phase,
which is associated with plasma leakage. In PAF levels in patients
with uncomplicated DF remained below 100ng/ml throughout
the course of the illness. The S1P levels were signiﬁcantly lower
(p =0.005) in those with DHF (mean 5.76, SD±3.1mol/l) when
compared to thosewithDF (mean11.34; SD6.1mol/l) andhealthy
individuals. Imaging studies using HUVEC cell lines showed that
ZO-1 protein was disrupted at higher concentration of PAF which
was blocked by use of a PAF antagonist. PAF levels appear to be
signiﬁcantly high in patients with acute dengue infection and SIP
signiﬁcantly lower suggesting that the delicate balance between
these mediators might have a role in the pathogenesis of vascular
leak in acute dengue.
http://dx.doi.org/10.1016/j.ijid.2014.03.475
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WHO ART guidelines and beyond: Should CD4
count be a barrier to ART initiation
F. Venter
Wits Reproductive Health and HIV Institute,
Johannesburg, South Africa
WHO 2013 guidelines suggest that the CD4 threshold for
antiretroviral initiation be elevated from 350 to 500 cells/ul, in
patients with HIV. This follows many (but not all) developed coun-
try guidelines, which have elevated the threshold or done away
with it altogether, based on data suggesting clinical beneﬁt, as well
as modelling studies showing signiﬁcant public health beneﬁt in
arresting new transmission. However, there has been criticism of
the new recommendation on many fronts, ranging from question-
ing of the absolute clinical beneﬁt to the individual starting early,
the extent of the HIV prevention beneﬁts of earlier initiation, to
concerns regarding the cost and operational feasibility of expand-
ing analreadyambitiousprogrammebeyondcurrentCD4strata.On
the other side, a signiﬁcant number of clinicians and public health
advocates have called for WHO to remove the CD4 threshold alto-
gether, to simplifyprogrammes, aswell asmaximise theprevention
power of antiretrovirals. This presentation will explore both sides
of the recommendation.
http://dx.doi.org/10.1016/j.ijid.2014.03.476
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Monitoring antiretroviral therapy in
resource-limited settings
K. Ruxrungtham
HIV Netherlands Australia Thailand Research
Collaboration, The Thai Red Cross AIDS Research
Center and Chulalongkorn University, Bangkok,
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The recent WHO 2013 consolidated ART guidelines have rec-
ommended to initiated ART earlier in asymptomatic HIV-infected
individuals when CD4 count <500 cells/mm3. Several resource-
limited countries are thus implementing earlier ART. Ideally, in
settings where primary HIV resistance transmission is low and
patients are very well adhere to the treatment regimen; most
patients will have a long-term virological control regardless of VL
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monitoring. In reality however, a signiﬁcant number of healthcare
providers (HCPs) do not have good HIV care experiences while
having serious service workload, prescribing ARVs without proper
laboratory monitoring may lead to more proportion of patients
with virological failure and HIV drug resistance. For RLS, it is
therefore important to implement some proper and cost-effective
monitoring strategies while operating earlier ART policy.
Inprinciples, goodHCP-patient relationship toensure treatment
adherence is “the must do” and the most cost-effective measure.
Each RLS should consider a minimal set of laboratory tests to be
included in their services such as CBC, creatinine (before initiating
TDF) for safety; TB screening and VDRL for co-infection screening.
In case of ART efﬁcacy, CD4 at baseline then 2 times a year until
CD4>350; and as long as VL is well suppressed, we may not need
further testing. WHO 2013 has recommended to perform VL test, if
available it should be tested every 6 months until becoming unde-
tectable then once a-year. There are more low cost (<3 USD/test)
and point-of-care (POC) CD4 tests available commercially. Low cost
POC VL-test is not yet available. Current low cost VL test in some
RLS is based on a homebrew real-time PCR assay (cost < 5USD/test).
However, it requires expensive equipments and experience tech-
nicians to run the service. While POC VL tests in not yet available,
HIV care system in RLS may consider setting up few central labs
to provide low cost homebrew VL test and validate the dried-
blood spot sample testing systems. Nonetheless, in settings where
resources are truly constraint, it should not prevent from imple-
menting ART for HIV symptomatic patients or thosewith CD4<350
if someessential labmonitoring isnot available.Allmeans toensure
adherence is warranted.
http://dx.doi.org/10.1016/j.ijid.2014.03.477
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Timing of antiretroviral therapy in relation to
co-morbidities
R. Gulick
Weill Cornell Medical College, New York, NY, USA
Antiretroviral therapy (ART) for HIV infection decreases HIV
RNA levels, increases CD4 cell counts and general immune func-
tion, prevents clinical progression, and prolongs survival. Despite
these clear beneﬁts, the optimal time of initiation of ART remains
uncertain. ART treatment guidelines worldwide agree in the rec-
ommendation to start ART in anyHIV-infected patientwith AIDS or
symptomatic HIV disease. Despite concerns about drug toxicities,
drug interactions, and the immune reconstitution syndrome, start-
ing ART earlier during an acute opportunistic infection (including
tuberculosis) clearlywasassociatedwithclinical beneﬁts, including
prolonged survival, in randomized clinical studies.More controver-
sial is the timing of starting ART during an acute central nervous
system opportunistic infection such as cryptococcosis or tuber-
culosis with some randomized clinical studies suggesting earlier
ART was associated with increased mortality. ART guidelines dif-
fer in their recommendations for starting ART in asymptomatic
patients. Some guidelines base their recommendations for start-
ing ART on speciﬁc CD4 cell count thresholds and/or the presence
of any of a number of co-morbidities such as hepatitis B, hep-
atitis C, non-AIDS malignancies requiring treatment, idiopathic
thrombocytopenic purpura (ITP), increased cardiovascular risk,
neurocognitive changes, renal disease including HIV-associated
nephropathy (HIVAN), and active or latent tuberculosis. Despite
the disagreement in treatment guidelines about the optimal time
to start ART in asymptomatic patients, there is a clear trend for
starting ART earlier in HIV infection. For example, World Health
Organization (WHO) treatment guidelines have increased CD4
cell count thresholds for starting ART from 200/uL to 350/uL
to 500/uL in recent years. Part of the rationale for starting ART
earlier is to avoid non-AIDS comorbidities that may be associ-
ated with the inﬂammation and immune activation associated
with untreated HIV infection, including cardiovascular, renal,
liver, neurologic, andmalignant diseases. Additional observational,
interventional, and randomized clinical studies are in progress
and will help inform the important decision of when to start
ART.
http://dx.doi.org/10.1016/j.ijid.2014.03.478
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Access to antiretroviral therapy: Successes,
challenges and future
G. Van Cutsem
Médecins Sans Frontières & University of Cape
Town, Cape Town, South Africa
The number of people living with HIV accessing antiretroviral
treatment in resource-limited countries has increased from a few
thousands pre-2000 to almost 10million in 2013. This achievement
is unprecedented in the history of public health and has resulted in
important decreases in HIV-related mortality, including a 10 year
increase in life expectancy in South Africa. Yet, this scale up is not
without problems. Retention in care is poor, data on virological
success rates is scarce, signiﬁcant numbers of patients are seek-
ing health carewith advanced immunosuppression, and increasing
medicine stock outs are symptomatic of the limits of existinghealth
systems. According to the latest WHO guidelines, another 16 mil-
lion people are in need of ART,most ofwhomdonot know their HIV
status. This presentation examines the factors contributing to the
success of the ART scale up, the challenges it faces, and strategies
to scale up further whilst maintaining quality of care.
This presentation examines the factors contributing to the suc-
cess of the ART scale up, the challenges it faces, and strategies to
scale up further whilst maintaining quality of care.
A number of critical historical factors have made this success
possible: strong activist movements in rich and poor countries,
massive increases in vertical funding, the Doha declaration on
TRIPS agreement and public health, generic competition resulting
in prices of ﬁrst line ART decrease from over 10,000 USD to less
than 100 USD per patient per year, programmatic innovations and
paradigm shifts in public health and political will. Yet the success
is unequally distributed and access to ART remains low in many
countries (such as most of central and west Africa) and popula-
tions (e.g. intravenous drug users). Challenges include losses along
the test to treatment cascade, treatment failure, pediatric and ado-
lescentHIV,medicine stock outs, overburdenedhealth systems and
